Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1103 results about "Bispecific antibody" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Method for making multispecific antibodies having heteromultimeric and common components
InactiveUS7183076B2Increased formationIncrease productionAnimal cellsAntibody mimetics/scaffoldsSpecific immunityBispecific antibody
The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method futher involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and / or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide. The method allows for the enhanced formation of the desired heteromultimer relative to undesired heteromultimers and homomultimers.
Owner:GENENTECH INC
Readily Isolated Bispecific Antibodies with Native Immunoglobulin Format
ActiveUS20100331527A1Improve abilitiesReduces and eliminates bindingHybrid immunoglobulinsSerum immunoglobulinsImmunoglobulin heavy chainHeavy chain
A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.
Owner:REGENERON PHARM INC
Methods for Producing Polypeptides by Regulating Polypeptide Association
ActiveUS20100015133A1Efficient productionEfficient formationAnimal cellsSugar derivativesHeterologousAntiendomysial antibodies
In the course of the present invention, it was discovered that one could regulate association between polypeptides by modifying amino acid residues that form the interface during the association to amino acids carrying the same type of charge. In this context, the present invention enables efficient formation of heterologous molecules. For example, the present invention can be suitably applied to the preparation of bispecific antibodies.
Owner:CHUGAI PHARMA CO LTD
Method for making heteromultimeric polypeptides
InactiveUS7642228B2Increase productionAntibacterial agentsPeptide/protein ingredientsCrystallographyAmino acid side chain
Owner:GENENTECH INC
Method for making heteromultimeric polypeptides
InactiveUS20070014794A1Increase productionAntibacterial agentsPeptide/protein ingredientsCrystallographyAmino acid side chain
The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves introducing a protuberance at the interface of a first polypeptide and a corresponding cavity in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heteromultimer formation and hinder homomultimer formation. “Protuberances” are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory “cavities” of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). The protuberance and cavity can be made by synthetic means such as altering the nucleic acid encoding the polypeptides or by peptide synthesis.
Owner:GENENTECH INC
Bivalent, bispecific antibodies
ActiveUS20090162360A1Increase heterodimerisationIncrease productionAnimal cellsHybrid immunoglobulinsBispecific antibodySpecific antibody
Owner:F HOFFMANN LA ROCHE & CO AG
Methods of modifying antibodies for purification of bispecific antibodies
ActiveUS20090263392A1Efficient purificationFunction increaseSugar derivativesAntibody ingredientsAntiendomysial antibodiesBinding site
The present inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column based on the difference in isoelectric points between the H chains of two types of antibodies, wherein the difference is introduced by modifying the amino acids present on the surface of the antibody variable regions of two types of antibodies that constitute a bispecific antibody. Furthermore, the inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column by linking respective antigen binding sites (heavy chain variable regions) to the antibody constant regions having different isoelectric points, and then coexpressing these antibodies.
Owner:CHUGAI PHARMA CO LTD
Bispecific antibody devoid of Fc region and method of treatment using same
InactiveUS20060263367A1Efficient productionAvoids undesirable effector functionHybrid immunoglobulinsImmunoglobulins against cell receptors/antigens/surface-determinantsBispecific antibodyAntigen binding
Bispecific antibody derivatives are disclosed which are comprised of a first region which binds to a first antigen and a second region which binds to a second antigen different from the first antigen. The first and second regions of the bispecific antibody are each stabilized by an additional internal disulfide bridge, and connected by a flexible polypeptide linker. The bispecific antibody is devoid of an Fc portion and is encoded as a single chain-sequence.
Owner:FRIEDRICH ALEXANDER UNIV ERLANGEN NURNBERG
Bivalent, bispecific antibodies
InactiveUS20090162359A1Increase productionImprove purification effectAnimal cellsHybrid immunoglobulinsBispecific antibodySpecific antibody
Owner:F HOFFMANN LA ROCHE & CO AG
Bivalent, bispecific antibodies
ActiveUS20090232811A1Increase productionImprove purification effectAnimal cellsAntibody mimetics/scaffoldsBispecific antibodySpecific antibody
Owner:F HOFFMANN LA ROCHE & CO AG
Production and use of novel peptide-based agents for use with bi-specific antibodies
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been prepared. The antigenic linker is conjugated to one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them.
Owner:IMMUNOMEDICS INC
Bivalent, bispecific antibodies
InactiveUS20090175851A1Increase productionImprove purification effectAntibacterial agentsAntibody mimetics/scaffoldsBispecific antibodySpecific antibody
Owner:F HOFFMANN LA ROCHE INC
Bispecific antibodies
ActiveUS7235641B2Improve productivityImprove efficiencyAntipyreticAntibody mimetics/scaffoldsBispecific antibodyImmune effector cell
Owner:AMGEN RES (MUNICH) GMBH
Bispecific Antibody Point Mutations for Enhancing Rate of Clearance
A mutant bispecific antibody that includes (a) a human hinge constant region from IgG having one or more amino acid mutations in the CH2 domain, (b) two scFvs; and (c) two Fvs has been constructed. This type of antibody displays enhanced clearance, which has been found to be particularly useful in the context of pre-targeting methods.
Owner:IMMUNOMEDICS INC
Methods for generating multimeric molecules
InactiveUS20050136051A1Immunoglobulins against blood coagulation factorsHybrid immunoglobulinsBispecific antibodyIn vivo
Owner:SCALLON BERNARD
Method for making multispecific antibodies having heteromultimeric and common components
InactiveUS7951917B1Increased formationIncrease productionHybrid immunoglobulinsAntibody ingredientsSpecific immunityBispecific antibody
The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method further involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and / or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide. The method allows for the enhanced formation of the desired heteromultimer relative to undesired heteromultimers and homomultimers.
Owner:GENENTECH INC
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
InactiveUS20130045492A1Reduce in quantitySimple methodAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsEpitopeProtein insertion
A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided.
Owner:REGENERON PHARM INC
Bivalent, bispecific antibodies
InactiveUS8227577B2Raise the ratioIncrease productionAntibacterial agentsAntibody mimetics/scaffoldsAntiendomysial antibodiesBispecific antibody
Owner:F HOFFMANN LA ROCHE INC
Human monoclonal antibodies against bacillus anthracis protective antigen
ActiveUS20050287149A1Neutralizing activityLess immunogenicAntibacterial agentsBacteriaV(D)J recombinationBispecific antibody
Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
Owner:MEDAREX LLC
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
InactiveUS7074405B1Increased toxicityLow toxicityHybrid immunoglobulinsInorganic boron active ingredientsEpitopeDiagnostic agent
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate. The targetable conjugate comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable conjugate further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.
Owner:IMMUNOMEDICS INC
Bi-specific antibodies for pre-targeting diagnosis and therapy
InactiveUS7052872B1Increased toxicityLow toxicityIn-vivo radioactive preparationsSugar derivativesEpitopeDiagnostic agent
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate. The targetable conjugate comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable conjugate further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.
Owner:IMMUNOMEDICS INC
Therapeutic using a bispecific antibody
Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or diagnostic agents, autoantibodies, anti-graft antibodies, and other undesirable compounds may be induced using the multivalent, multispecific molecules.
Owner:IMMUNOMEDICS INC
Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
ActiveUS20070264265A1Avoid infectionReduce eliminateOrganic active ingredientsAntiviralsDiagnostic agentBinding site
The present invention concerns methods and compositions for treatment of HIV infection in a subject. The compositions may comprise a targeting molecule against an HIV antigen, such as an anti-HIV antibody or antibody fragment. The anti-HIV antibody or fragment may be conjugated to a variety of cytotoxic agents, such as doxorubicin. In a preferred embodiment, the antibody or fragment is P4 / D10. Other embodiments may concern methods of imaging, detection or diagnosis of HIV infection in a subject using an anti-HIV antibody or fragment conjugated to a diagnostic agent. In alternative embodiments, a bispecific antibody with at least one binding site for an HIV antigen and at least one binding site for a carrier molecule may be administered, optionally followed by a clearing agent, followed by administration of a carrier molecule conjugated to a therapeutic agent.
Owner:IMMUNOMEDICS INC
Methods and Antibody Compositions for Tumor Treatment
ActiveUS20150266966A1Decreased killing of T-cellsReduce the burden onImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsDiseaseCD20
The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile with regard to Fcγ receptors. The bispecific antibodies are engineered to efficiently induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, a second antigen-binding molecule that specifically binds human CD20, and an Fc domain that binds Fcγ receptors with a specific binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20. The bispecific antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.
Owner:REGENERON PHARM INC
Human monoclonal antibodies against CD30
ActiveUS7387776B2Good curative effectInhibit growth/mediate killingAntipyreticAnalgesicsV(D)J recombinationBispecific antibody
Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
Owner:ER SQUIBB & SONS INC
Bispecific antibodies
ActiveUS20050136050A1Less complexReduce in quantityAntipyreticAntibody mimetics/scaffoldsBispecific antibodyImmune effector cell
The present invention discloses bispecific antibodies comprising two antibody variable domains on a single polypeptide chain, wherein a first portion of the bispecific antibody is capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen on the human immune effector cell, the first portion consisting of one antibody variable domain, and a second portion of the bispecific antibody specifically binding to a target antigen other than the effector antigen, the target antigen on a target cell other than the human immune effector cell, the second portion comprising one antibody variable domain.
Owner:AMGEN RES (MUNICH) GMBH
Bispecific antibodies
InactiveUS20060018897A1Immunoglobulins against animals/humansAntibody ingredientsBispecific antibodyEndocrinology
Owner:TRANSTARGET
Bispecific Anti-egfr/Anti-igf-1r antibodies
InactiveUS20100081796A1Hybrid immunoglobulinsImmunoglobulins against cell receptors/antigens/surface-determinantsBispecific antibodyTreatment use
Owner:ROCHE GLYCART AG
Humanized antibodies against CD3
Owner:ABBOTT BIOTHERAPEUTICS CORP
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
InactiveUS20030198595A1Increase productionImproved chemotherapyAntibacterial agentsUltrasonic/sonic/infrasonic diagnosticsEpitopeDiagnostic agent
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.
Owner:IMMUNOMEDICS INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com